Trying to sell a diabetes drug (SGLT2 inhibitor) for around $1.50 a pill vs the $20 industry norm
Al Collinson of TheracosBio discusses his plan to sell the SGLT2 inhibitor Brenzavvy for a deeply discounted price compared to larger competitors on the market.
Comentários